[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cogent Biosciences Inc (COGT)

Cogent Biosciences Inc (COGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,901,781
  • Shares Outstanding, K 170,868
  • Annual Sales, $ 0 K
  • Annual Income, $ -328,940 K
  • EBIT $ -362 M
  • EBITDA $ -361 M
  • 60-Month Beta 0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.87

Options Overview Details

View History
  • Implied Volatility 64.73% (+7.63%)
  • Historical Volatility 43.02%
  • IV Percentile 6%
  • IV Rank 3.82%
  • IV High 370.26% on 07/03/25
  • IV Low 52.58% on 05/20/26
  • Expected Move (DTE 25) 1.28 (3.56%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,435
  • Volume Avg (30-Day) 557
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 18,840
  • Open Int (30-Day) 22,647
  • Expected Range 34.57 to 37.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.55
  • Number of Estimates 6
  • High Estimate $-0.44
  • Low Estimate $-0.66
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) -3.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.93 +15.87%
on 06/10/26
36.03 -0.53%
on 06/22/26
+3.17 (+9.70%)
since 05/22/26
3-Month
30.87 +16.10%
on 05/19/26
39.41 -9.06%
on 03/31/26
+2.46 (+7.37%)
since 03/20/26
52-Week
6.92 +417.92%
on 06/23/25
43.73 -18.04%
on 12/08/25
+28.61 (+395.71%)
since 06/20/25

Most Recent Stories

More News
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

-  JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor,...

COGT : 35.84 (+3.76%)
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –...

COGT : 35.84 (+3.76%)
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI:...

COGT : 35.84 (+3.76%)
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30, 2026 ...

COGT : 35.84 (+3.76%)
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 35.84 (+3.76%)
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings   Preclinical...

COGT : 35.84 (+3.76%)
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation...

COGT : 35.84 (+3.76%)
Cogent Biosciences: The Pipeline Distraction That Might Obscure What Actually Matters Tomorrow

Barchart Research What to Expect from COGT Earnings COGT Generated May 4, 2026 Current Price $36.73 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 17.24% Cogent Biosciences: The Pipeline...

COGT : 35.84 (+3.76%)
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

COGT : 35.84 (+3.76%)
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

– Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors ...

COGT : 35.84 (+3.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cogent Biosciences Inc. is a biotechnology company. It is focused on developing precision therapies for genetically defined diseases. The company's program consist PLX9486. Cogent Biosciences Inc., formerly known as Unum Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 37.25
2nd Resistance Point 36.64
1st Resistance Point 36.24
Last Price 35.84
1st Support Level 35.23
2nd Support Level 34.62
3rd Support Level 34.22

See More

52-Week High 43.73
Last Price 35.84
Fibonacci 61.8% 29.67
Fibonacci 50% 25.33
Fibonacci 38.2% 20.98
52-Week Low 6.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.